Our findings provided the first evidence that the NRF2/miR-196a/GLTP pathway was an important mechanism of gefitinib resistance, and miR-196a and GLTP may be used as new biomarkers for gefitinib resistance and clinical therapeutic outcomes of lung cancer. This evidence concerns the gene NFE2L2 and lung cancer.